Sort
15,273 grants matching “antimicrobial resistance”
Multiplexed, Non-Amplified, Nucleic Acid-Based Identification of Multidrug Resistant Pathogens Using an Integrated Optofluidic Platform
$1,069,803Aaron R. Hawkins · Brigham Young University · R01 · FY2016 · AI
Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance
$1,069,209George Drusano · University Of Florida · N01 · FY2012 · AI
Bioinformatics Core
$1,067,373Vaughn Cooper · Boston Children'S Hospital · U19 · FY2024 · AI
Structural characterization of OM proteins from Gram-negative pathogens
$1,064,828Susan Buchanan · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
Identification of novel MDR antimicrobials from symbioses between terrestrial and marine invertebrates and rare microbial taxa
$1,064,370Timothy S Bugni · University Of Wisconsin-Madison · U19 · FY2019 · AI
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses
$1,061,111Cameron Robert Currie · University Of Wisconsin-Madison · U19 · FY2021 · AI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ
$1,059,804Jian Li · Monash University · R01 · FY2017 · AI
IMPDH-targeted antibiotics for select agents
$1,058,736Lizbeth K. Hedstrom · Brandeis University · R01 · FY2015 · AI
IMPDH-targeted antibiotics for select agents
$1,058,736Lizbeth K. Hedstrom · Brandeis University · R01 · FY2012 · AI
IMPDH-targeted antibiotics for select agents
$1,058,736Lizbeth K. Hedstrom · Brandeis University · R01 · FY2014 · AI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae
$1,058,081Zachary David Aron · Microbiotix, Inc · R01 · FY2020 · AI
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa
$1,057,733David Elihu Greenberg · Ut Southwestern Medical Center · R01 · FY2021 · AI
Venous Window Access Catheter For Hemodialysis
$1,057,200Steven Wayne Johnson · Vital Access, Inc. · R44 · FY2009 · CA
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses
$1,057,133Cameron Robert Currie · University Of Wisconsin-Madison · U19 · FY2019 · AI
Targeted natural product diversification to identify novel antibacterial agents
$1,055,950Erin Elizabeth Carlson · Trustees Of Indiana University · DP2 · FY2011 · OD
Sexually Transmitted Infections Clinical Trials Group
$1,055,787Klausner Jeffrey · Social And Scientific Systems, Inc. · N01 · FY2017 · AI
Optimized Combination Antimalarial Drug Therapy
$1,055,093Paul D. Roepe · Georgetown University · R01 · FY2014 · AI
Advanced Development of a Combined Shigella-ETEC Vaccine
$1,053,471Eileen M. Barry · University Of Maryland Baltimore · R01 · FY2023 · AI
Novel pre-coital, non-hormonal multipurpose prevention technology (MPT)
$1,052,922Pavimol Angsantikul · Population Council · R01 · FY2021 · AI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae
$1,052,607Michelle M. Butler · Microbiotix, Inc · R01 · FY2021 · AI
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections
$1,051,346David S Perlin · Hackensack University Medical Center · R01 · FY2020 · AI
Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds
$1,050,000Manav Mehta · Gel4med, Inc. · R44 · FY2025 · AI
Comparing Placebo versus Antibiotics for Acute Uncomplicated Diverticulitis
$1,050,000Alexander Tharrington Hawkins · Vanderbilt University Medical Center · R01 · FY2025 · DK
Direct detection and identification of antimicrobial resistance genes in bloodstream infections
$1,050,000Alon Singer · Helixbind, Inc. · R44 · FY2022 · AI
Diagnostic tool for assessment and tracking of microbial load in bloodstream infections
$1,050,000Alon Singer · Helixbind, Inc. · R44 · FY2023 · AI